Kazuto Nishio

22.3k citations

532 papers · 16.2k indexed · 1 hit paper · h-index 69

Oncology top 0.1%
Molecular Biology top 0.5%
Pulmonary and Respiratory Medicine top 0.1%
Cancer Research top 0.2%
Pathology and Forensic Medicine top 0.5%

Co-authors: Nagahiro Saijo Kazuko Sakai Kazuhiko Nakagawa Tokuzo Arao Isamu Okamoto Tomohide Tamura Yoshihiko Fujita Hideharu Kimura
Topics: Lung Cancer Treatments and Mutations (179 papers)Cancer Genomics and Diagnostics (77 papers)Colorectal Cancer Treatments and Studies (76 papers)
Cited by: Oncology Cancer Research Pulmonary and Respiratory Medicine
Journals: Journal of Clinical Investigation Journal of Clinical Oncology Blood
Partner nations: Japan United States United Kingdom

In The Last Decade

Kazuto Nishio

512 papers receiving 15.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice.

2003 515 citations Kazuto Nishio et al. profile →

Peers

Countries citing papers authored by Kazuto Nishio

Since Specialization

Citations

This map shows the geographic impact of Kazuto Nishio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kazuto Nishio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kazuto Nishio more than expected).

Fields of papers citing papers by Kazuto Nishio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kazuto Nishio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kazuto Nishio. The network helps show where Kazuto Nishio may publish in the future.

Co-authorship network of co-authors of Kazuto Nishio

This figure shows the co-authorship network connecting the top 25 collaborators of Kazuto Nishio. A scholar is included among the top collaborators of Kazuto Nishio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kazuto Nishio. Kazuto Nishio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	KRAS Inhibitor Resistance in MET -Amplified KRAS G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms 2021 ·Clinical Cancer Research ·Shinichiro Suzuki,Kimio Yonesaka,Takeshi Teramura,Toshiyuki Takehara,Ryoji Kato,Hitomi Sakai,Koji Haratani,Junko Tanizaki,Hisato Kawakami,Hidetoshi Hayashi,Kazuko Sakai,Kazuto Nishio,Kazuhiko Nakagawa	66
2	Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer 2016 ·Molecular Cancer Therapeutics ·Yoshihisa Kobayashi,Koichi Azuma,Hiroki Nagai,Young Hak Kim,Yosuke Togashi,(unknown),Masato Chiba,Masaki Shimoji,Katsuaki Sato,Kenji Tomizawa,Toshiki Takemoto,Kazuto Nishio,Tetsuya Mitsudomi	57
3	Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC 2016 ·Molecular Cancer Therapeutics ·Yu Nakamura,Yosuke Togashi,Hirokazu Nakahara,Shuta Tomida,Eri Banno,Masato Terashima,Hidetoshi Hayashi,Marco A. De Velasco,Kazuko Sakai,Yoshihiko Fujita,Takatsugu Okegawa,Kikuo Nutahara,Suguru Hamada,Kazuto Nishio	13
4	Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2 2016 ·Clinical Cancer Research ·Masato Terashima,Yosuke Togashi,Katsuaki Sato,Hiroshi Mizuuchi,Kazuko Sakai,Kenichi Suda,Yu Nakamura,Eri Banno,Hidetoshi Hayashi,Marco A. De Velasco,Yoshihiko Fujita,Shuta Tomida,Tetsuya Mitsudomi,Kazuto Nishio	15
5	EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs 2015 ·Clinical Cancer Research ·Yoshihisa Kobayashi,Yosuke Togashi,Yasushi Yatabe,Hiroshi Mizuuchi,Park Jangchul,(unknown),Masaki Shimoji,Katsuaki Sato,Kenichi Suda,Kenji Tomizawa,(unknown),Toyoaki Hida,Kazuto Nishio,Tetsuya Mitsudomi	164
6	The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile 2013 ·Molecular Cancer Therapeutics ·Hidenori Fujita,Kazutaka Miyadera,Masanori Kato,(unknown),(unknown),(unknown),Kimihiro Ito,Yoshimi Aoyagi,Toru Takenaka,Takamasa Suzuki,Satoko Ito,Akihiro Hashimoto,(unknown),(unknown),Hideki Kazuno,(unknown),Kazuto Nishio,Kazuhiko Yonekura	30
7	Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer 2012 ·Clinical Cancer Research ·Junko Tanizaki,Isamu Okamoto,Takafumi Okabe,Kazuko Sakai,Kaoru Tanaka,Hidetoshi Hayashi,Hiroyasu Kaneda,Ken Takezawa,Kiyoko Kuwata,Haruka Yamaguchi,Erina Hatashita,Kazuto Nishio,Kazuhiko Nakagawa	126
8	Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification 2012 ·Molecular Cancer Therapeutics ·Wataru Okamoto,Isamu Okamoto,Tokuzo Arao,Kiyoko Kuwata,Erina Hatashita,Haruka Yamaguchi,Kazuko Sakai,Kazuyoshi Yanagihara,Kazuto Nishio,Kazuhiko Nakagawa	73
9	Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors 2011 ·Clinical Cancer Research ·Kazuhiko Yamada,Noboru Yamamoto,Yasuhide Yamada,Hiroshi Nokihara,Yutaka Fujiwara,Taizo Hirata,Fumiaki Koizumi,Kazuto Nishio,Noriyuki Koyama,Tomohide Tamura	140
10	Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma 2011 ·Molecular Cancer Therapeutics ·Tomoyuki Nagai,Tokuzo Arao,Kazuyuki Furuta,Kazuko Sakai,Kanae Kudo,Hiroyasu Kaneda,Daisuke Tamura,Keiichi Aomatsu,Hideharu Kimura,Yoshihiko Fujita,Kazuko Matsumoto,Nagahiro Saijo,Masatoshi Kudo,Kazuto Nishio	101
11	Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer 2011 ·Clinical Cancer Research ·Ken Takezawa,Isamu Okamoto,Kazuto Nishio,Pasi A. Jänne,Kazuhiko Nakagawa	115
12	Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors 2010 ·Molecular Cancer Therapeutics ·Isamu Okamoto,Hiroyasu Kaneda,Taroh Satoh,Wataru Okamoto,Masaki Miyazaki,Ryotaro Morinaga,Shinya Ueda,Masaaki Terashima,Asuka Tsuya,Akiko Sarashina,(unknown),Tokuzo Arao,Kazuto Nishio,R. Kaiser,Kazuhiko Nakagawa	79
13	Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase–Targeted Agents in Non–Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor 2010 ·Molecular Cancer Therapeutics ·Ken Takezawa,Isamu Okamoto,Junko Tanizaki,Kiyoko Kuwata,Haruka Yamaguchi,Masahiro Fukuoka,Kazuto Nishio,Kazuhiko Nakagawa	63
14	FOXQ1 Is Overexpressed in Colorectal Cancer and Enhances Tumorigenicity and Tumor Growth 2010 ·Cancer Research ·Hiroyasu Kaneda,Tokuzo Arao,Kaoru Tanaka,Daisuke Tamura,Keiichi Aomatsu,Kanae Kudo,Kazuko Sakai,Marco A. De Velasco,Kunio Matsumoto,Yoshihiko Fujita,Yasuhide Yamada,Junji Tsurutani,Isamu Okamoto,Kazuhiko Nakagawa,Kazuto Nishio	157
15	Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo 2010 ·Clinical Cancer Research ·Kanae Kudo,Tokuzo Arao,Kaoru Tanaka,Tomoyuki Nagai,Kazuyuki Furuta,Kazuko Sakai,Hiroyasu Kaneda,Kazuko Matsumoto,Daisuke Tamura,Keiichi Aomatsu,Marco A. De Velasco,Yoshihiko Fujita,Nagahiro Saijo,Masatoshi Kudo,Kazuto Nishio	31
16	Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition 2010 ·Molecular Cancer Therapeutics ·Wataru Okamoto,Isamu Okamoto,Takeshi Yoshida,Kunio Okamoto,Ken Takezawa,Erina Hatashita,Yuki Yamada,Kiyoko Kuwata,Tokuzo Arao,Kazuyoshi Yanagihara,Masahiro Fukuoka,Kazuto Nishio,Kazuhiko Nakagawa	58
17	Role of Survivin in EGFR Inhibitor–Induced Apoptosis in Non–Small Cell Lung Cancers Positive for EGFR Mutations 2010 ·Cancer Research ·Kunio Okamoto,Isamu Okamoto,Wataru Okamoto,Kaoru Tanaka,Ken Takezawa,Kiyoko Kuwata,Haruka Yamaguchi,Kazuto Nishio,Kazuhiko Nakagawa	75
18	mTOR Signal and Hypoxia-Inducible Factor-1α Regulate CD133 Expression in Cancer Cells 2009 ·Cancer Research ·Kunio Matsumoto,Tokuzo Arao,Kaoru Tanaka,Hiroyasu Kaneda,Kanae Kudo,Yoshihiko Fujita,Daisuke Tamura,Keiichi Aomatsu,Tomohide Tamura,Yasuhide Yamada,Nagahiro Saijo,Kazuto Nishio	114
19	N-myc Downstream Regulated Gene 1/Cap43 Suppresses Tumor Growth and Angiogenesis of Pancreatic Cancer through Attenuation of Inhibitor of κB Kinase β Expression 2009 ·Cancer Research ·Fumihito Hosoi,Hiroto Izumi,Akihiko Kawahara,Yûichi Murakami,Hisafumi Kinoshita,Masayoshi Kage,Kazuto Nishio,Kimitoshi Kohno,Michihiko Kuwano,Mayumi Ono	88
20	EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line 2008 ·Molecular Cancer Therapeutics ·Junya Fukai,Hideyuki Yokote,Ryuya Yamanaka,Tokuzo Arao,Kazuto Nishio,Toru Itakura	113

About Kazuto Nishio

Kazuto Nishio is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 532 papers that have together received 16.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (179 papers), Cancer Genomics and Diagnostics (77 papers) and Colorectal Cancer Treatments and Studies (76 papers). The work is most often cited by research in Oncology (8.0k citations), Cancer Research (3.5k citations) and Pulmonary and Respiratory Medicine (6.2k citations). Kazuto Nishio has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Nagahiro Saijo, Kazuko Sakai, Kazuhiko Nakagawa, Tokuzo Arao, Isamu Okamoto, Tomohide Tamura, Yoshihiko Fujita, Hideharu Kimura, Fumiaki Koizumi and Masayuki Takeda. Their work appears in journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact